Genetic markers of inflammation may not contribute to metabolic traits in Mexican children.

Neeti Vashi, Carolina Stryjecki, Jesus Peralta-Romero, Fernando Suarez, Jaime Gomez-Zamudio, Ana I. Burguete-Garcia, Miguel Cruz, David Meyre

Background. Low-grade chronic inflammation is a common feature of obesity and its cardio-metabolic complications. However, little is known about a possible causal role of inflammation in metabolic disorders. Mexico is among the countries with the highest obesity rates in the world and the admixed Mexican population is a relevant sample due to high levels of genetic diversity. Method. Here, we studied 1462 Mexican children recruited from Mexico City. Six genetic variants in 5 inflammation-related genes were genotyped: rs1137101 (LEPR), rs7305618 (HNF1A), rs1800629 (TNFA), rs1800896, rs1800871 (IL-10), rs1862513 (RETN). Ten continuous and eight binary traits were assessed. Linear and logistic regression models were used adjusting for age, sex, and recruitment centre. Results. We found that one SNP displayed a nominal evidence of association with a continuous trait: rs1800871 (IL-10) with LDL (beta = -0.068 ± 1.006, P = 0.01). Subsequently, we found one nominal association with a binary trait: rs7305618 (HNF1A) with family history of hypertension (odds-ratio = 1.389 [1.054-1.829], P = 0.02). However, no P-value passed the Bonferroni correction for multiple testing. Discussion. Our data in a Mexican children population are consistent with previous reports in European adults in failing to demonstrate an association between inflammation-associated SNPs and metabolic traits.
Genetic markers of inflammation may not contribute to metabolic traits in Mexican children

Neeti Vashi¹, Carolina Stryjecki¹, Jesus Peralta-Romero², Fernando Suarez², Jaime Gomez-Zamudio², Ana I. Burguete-Garcia³, Miguel Cruz²,* David Meyre¹.4,*

¹Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; ²Medical Research Unit in Biochemistry, Hospital de Especialidades, Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social, Mexico City, Mexico; ³Centro de investigación sobre enfermedades infecciosas. Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico; ⁴Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.

Running title: SNPs, inflammation and metabolism

Corresponding author*: Dr. David Meyre. Department of Clinical Epidemiology and Biostatistics, McMaster University, Room 3205, Michael DeGroote Centre for Learning & Discovery, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada. Tel: 905.525.9140 Ext. 26802. Fax: 905.528.2814. Email: meyred@mcmaster.ca. Dr. Miguel Cruz, Unidad de Investigación Médica en Bioquímica, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Av. Cuauhtémoc, 330 C.P. 06725, México, D.F. Tel: 52 55 57612358; Fax: 5255 56276914. Email: mcruz1@yahoo.com.
Abstract

Background. Low-grade chronic inflammation is a common feature of obesity and its cardio-
metabolic complications. However, little is known about a possible causal role of inflammation
in metabolic disorders. Mexico is among the countries with the highest obesity rates in the world
and the admixed Mexican population is a relevant sample due to high levels of genetic diversity.

Method. Here, we studied 1462 Mexican children recruited from Mexico City. Six genetic
variants in 5 inflammation-related genes were genotyped: rs1137101 (LEPR), rs7305618
(HNF1A), rs1800629 (TNFA), rs1800896, rs1800871 (IL-10), rs1862513 (RETN). Ten
continuous and eight binary traits were assessed. Linear and logistic regression models were used
adjusting for age, sex, and recruitment centre.

Results. We found that one SNP displayed a nominal evidence of association with a continuous
trait: rs1800871 (IL-10) with LDL (beta = -0.068 ± 1.006, P = 0.01). Subsequently, we found one
nominal association with a binary trait: rs7305618 (HNF1A) with family history of hypertension
(odds-ratio = 1.389 [1.054-1.829], P = 0.02). However, no P-value passed the Bonferroni
correction for multiple testing.

Discussion. Our data in a Mexican children population are consistent with previous reports in
European adults in failing to demonstrate an association between inflammation-associated SNPs
and metabolic traits.
Introduction

Obesity has increased rapidly in prevalence over the last 30 years causing a growing public health burden at the worldwide level (Ogden et al. 2010). Obesity is no longer only a concern for high income countries, but is escalating in developing countries as well (Hossain et al. 2007). Even more concerning are the increasing rates of childhood obesity which have tripled over the last 30 years (Ogden et al. 2010). In 2011-2012, the age-adjusted prevalence of obesity in adults from the United States of America was 47.8%, 42.5%, 32.6% and 10.8% in non-Hispanic Blacks, Hispanics, non-Hispanic White Americans, and non-Hispanic Asians, respectively (Ogden et al. 2014). These discrepancies may be due to differences in diet, lifestyle, socioeconomic status and access to health care across ethnic groups. However they may also reflect differences in the genetic susceptibility to obesity and metabolic disorders as evidenced by admixture studies (Norden-Krichmar et al. 2014). Twin studies have reported heritability estimates between 47-90% for body mass index (BMI) (Elks et al. 2012). Eleven monogenic genes and more than 140 polygenic loci have been identified to date, accounting for a modest fraction of the heritability of obesity (Locke et al. 2015b; Yazdi et al. 2015). Obesity is associated with cardio-metabolic complications (insulin resistance, type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease) that cluster into the so-called metabolic syndrome (Walker et al. 2012). However, the relationship between obesity and associated complications is complex as obesity does not always convert into a metabolic syndrome (Karelis et al. 2004; Kramer et al. 2013). Consistent with the phenotypic correlations seen in observational epidemiology, shared genetic contributions between the components of the metabolic syndrome suggest that shared molecular roots may be involved in the development of the metabolic syndrome (Avery et al. 2011; van Vliet-Ostaptchouk et al. 2013; Vattikuti et al. 2012).
Inflammation has recently been advocated as one of the pathophysiological mechanisms linking obesity to other metabolic complications (Hotamisligil 2006). Inflammation can be defined as a protective response of an organism to infection and injury. This operates through initiating a healing process of pathogen killing and tissue repair to restore homeostasis at the infected and/or damaged sites (Hotamisligil 2006). Normally, the inflammatory response to harmful stimuli is short-lived and once the damage is removed or neutralized, the inflammation is resolved through negative feedback mechanisms (Hotamisligil 2006). However, inflammatory response that fails to regulate itself becomes chronic and is believed to set the stage for a broad range of diseases (Hotamisligil 2006). Obesity and its cardio-metabolic complications are associated with low-grade chronic inflammation, characterized by abnormal cytokine production, activation of a network of inflammatory signal pathways, and new connective tissue formation (Wellen & Hotamisligil 2005).

Genome-wide association and in a lesser extent candidate gene studies identified around fifty common genetic variants associated with serum inflammatory biomarker levels (e.g. C-reactive protein (CRP), soluble Intercellular Adhesion Molecule 1 (sICAM-1), interleukin-6 (IL-6) or soluble P-selectin) (Raman et al. 2013). Researchers then used these recently discovered genetic variants to determine whether this chronic inflammation is a cause of obesity and other metabolic disorders, or a consequence of it. Overall, Mendelian randomization experiments including gene variants in inflammation pathways did not evidence a causal role of inflammation in obesity or type 2 diabetes (Brunner et al. 2008; Rafiq et al. 2008; Welsh et al. 2010) and conflicting results about a causal link between inflammation and cardiovascular disease have been reported (Brunner et al. 2008; Consortium 2012; Raman et al. 2013; Varbo et al. 2013). At
this stage, more research is needed to understand the role of inflammation in the development of obesity and cardio-metabolic complications, particularly in non-European populations.

Metabolic syndrome is observed in childhood obesity, but can also develop in lean children, suggesting that obesity is a marker for the syndrome, not a cause (Elliott et al. 2009). Since obesity and its complications are associated with atherogenesis starting in childhood and early adulthood (Tounian et al. 2001; Weiss et al. 2013), a better understanding of the molecular mechanisms involved in the clustering of cardio-metabolic factors early in life may help to develop more efficient programs to prevent the development of metabolic syndrome.

The Mexican population is characterized by a high prevalence of obesity and metabolic complications. The 2012 National Health and Nutrition Survey indicates that 34.4% and 71.2% of the Mexican children and adults respectively are overweight or obese (León-Mimila et al. 2013; Tounian et al. 2001). This ranks Mexico among the countries with the highest obesity rates in the world (Barquera et al. 2009; León-Mimila et al. 2013). The prevalence of metabolic syndrome (ATP III criteria) in children and adolescents living in Mexico was estimated to be 20% in 2006 (Barquera et al. 2009; Castillo et al. 2007). Depending on the definitions used (American Heart Association/ National Heart, Lung, and Blood Institute or the International Diabetes Federation), the prevalence of metabolic syndrome among Mexican adults ranges from 59.7 to 68.7% (Castillo et al. 2007). This exceptionally high burden of obesity and metabolic syndrome in the Mexican population is largely due to the rapid transition towards an ‘obesogenic’ environment characterized by a sedentary lifestyle, an increase in the consumption of sugar-sweetened beverages coupled with the recent proliferation of fast food restaurants (Isordia-Salas et al. 2011). However, the tremendous genetic variety and unique genetic architecture of the admixed Mexican population may partly account for a higher
susceptibility to obesity and metabolic disturbances than in other populations (Rivera et al. 2002). Mexican populations consist of Native individuals as well as individuals of European or African descent (Rivera et al. 2002). The distributions and proportions of these three groups vary with the region studied however evidence shows very few true Natives remain as virtually all native groups show some degree of admixture, mainly with Europeans (Consortium 2014). Thus studying the Mexican population gives insight into the disease mechanisms of a variety of races due to the genetic diversity present in the population (Consortium 2014; Lisker 1996).

In this study, we assessed the association of 6 common genetic single nucleotide polymorphisms (SNPs) in 5 inflammation-related genes with 10 continuous and 8 binary metabolic traits in 1462 children from the Mexican population. Our data do not favor an association between inflammatory processes and the development of metabolic complications.

Methods

Study Participants

A total of 1462 unrelated children aged 6-14 having both genetic and phenotypic data available were included in this study. Children were randomly selected to participate in a cross-sectional study from four schools in Mexico City between July 2011 and July 2012. Anthropometric traits were assessed by a trained pediatrician. Blood samples were collected for biochemical measurements and DNA extraction. Information regarding family history of type 2 diabetes, obesity and hypertension was obtained via questionnaires. The study protocol was approved by the Mexican Social Security Institute National Committee and the Ethical Committee Board and all experiments were performed in accordance with relevant guidelines and regulations. Informed consent was obtained from both parents and the child.

Genotyping
Genomic DNA was extracted from peripheral blood using the FLEX STAR Autogen platform (Holliston, Massachusetts US). The genotyping was performed using the TaqMan OpenArray Real-Time PCR System (Life Technologies, Carlsbad, US), following the manufacturer’s instructions. We selected 6 SNPs in or near 5 genes that displayed redundant associations with inflammation-related traits in literature: rs1137101 (leptin receptor \((LEPR)\)), rs7305618 (hepatocyte nuclear factor 1 alpha \((HNF1A)\)), rs1800629 (tumor necrosis factor alpha \((TNFA)\)), rs1800896, rs1800871 (interleukin-10 \((IL-10)\)), rs1862513 (resistin \((RETN)\)) (Kilpelainen et al. 2010; Ortega et al. 2014; Raman et al. 2013; Wang et al. 2011). The 6 SNPs showed no deviation from Hardy-Weinberg Equilibrium \((0.22 \leq P \leq 0.76)\). The call rate for each of the 6 SNPs was comprised between 94.6 and 100 % (Supplementary Table 1). The two SNPs rs1800896 and rs1800871 in \(IL-10\) display modest linkage disequilibrium in the Mexican children study sample \((r^2 \text{ value } = 0.239)\).

**Phenotyping**

All participants were weighed using a digital scale (Seca, Hamburg, Germany). Height was measured with a portable stadiometer (Seca 225, Hamburg, Germany). Body mass index was calculated as weight \((\text{kg})\) / \((\text{height} \ (m)^2)\) and classified as underweight, normal weight, overweight, obese according to the Centers for Disease Control and Prevention CDC 2000 references. Waist circumference \((WC)\) and hip circumference \((HC)\) were measured at the midpoint between the lowest rib and the iliac crest at the top of the iliac crest respectively, after a normal exhalation with children in the standing position. Systolic and diastolic blood pressure \((SBP \text{ and } DBP)\) were measured using a mercurial sphygmomanometer (ALPK2, Tokyo, Japan). Blood pressure readings were taken for each participant twice on the right arm in a sitting position with a 5 minute rest between each measurement and the mean of the two readings was
Hypertension was defined as average measured blood pressure above the American Heart Association’s recommendations (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg). Blood samples were obtained following a 12 hour fast and were analyzed for fasting glucose, total cholesterol (TC), HDL-cholesterol (HDL), LDL-cholesterol (LDL) and triglycerides (TG) using the ILab 350 Clinical Chemistry System (Instrumentation Laboratory IL, Barcelona Spain). Insulin (IU) was measured by chemiluminescence (IMMULITE, Siemens, USA). The 2003 ADA criteria for fasting plasma glucose (FPG) were used to classify children as normal (FPG < 5.6 mmol/L), as having impaired fasting glucose (IFG; FPG 5.6–6.9 mmol/L), or as having T2D (FPG > 7.0 mmol/L) (Lisker et al. 1996). Subjects with IFG or T2D were considered as having hyperglycemia. Dyslipidemia was defined as fasting triglycerides ≥ 100 mg/dL (0-9 years of age) or triglycerides ≥ 130 mg/dL (10-19 years of age) and/or HDL-C < 35 mg/dL and/or LDL-C ≥ 130 mg/dL, according to current recommendations (Kalra et al. 2009). Information regarding family history of type 2 diabetes, overweight / obesity, and hypertension was obtained via questionnaires.

Statistical Analyses

Statistical analyses were performed using SPSS (version 20). We assessed the power of our sample using QUANTO software version 1.2.4 (University of Southern California, Los Angeles, CA, USA). Non-biological outlier data were discarded. Due to the risk of blood hemolysis, fasting insulin values < 1 mIU/l were discarded from the study. The normal distribution of continuous variables was tested using the Kolmogorov-Smirnov test. All traits of interest deviated significantly from normality. Logarithmic transformations corrected the lack of normality for fasting insulin, improved the distribution of six traits (BMI, waist and hip circumference, waist to hip ratio, total cholesterol, triglycerides,) despite still deviating from
normality, and did not improve the distribution of fasting glucose, HDL and LDL cholesterol. Linear regression models were used to examine the association between the SNPs and metabolic traits. These tests were adjusted for sex, age and the recruitment centre. Genetic association studies were performed under an additive mode of inheritance for 5 out of 6 SNPs and the effect allele was the minor allele. Because only one AA homozygous carrier was identified for rs1800629 (TNFA), we used a dominant model instead. Two-sided P < 0.05 before Bonferroni correction were considered as nominally significant. After applying a Bonferroni’s correction for multiple testing (18 binary / continuous traits x 6 SNPs), P-values < 4.6 x 10^{-4} (0.05/108) was considered as significant.

Results

Characteristics of the Mexican children population

The main anthropometric and biological characteristics of the 1462 Mexican children are summarized in Table 1. Fifty-three percent of the population were males. Children exhibited an average age and BMI of 9.24 ± 2.07 years and 19.65 ± 4.20 kg/m^2, respectively. Using the Centers for Disease Control and Prevention 2000 references, 1.4% of the children were underweight, 49.4% were normal weight, 21.3% were overweight and 27.9% were obese. Additionally, 1.5, 3.1 and 34.9% of children displayed hypertension, hyperglycemia, and dyslipidemia, respectively. A family history of overweight / obesity, type 2 diabetes or hypertension was reported for 53.0, 12.0 and 16.3% of children, respectively (Table 1). The sample size was similar for all traits except fasting insulin (data available in 78.5% of subjects) due to the phenomenon of blood hemolysis.

Association between genetic markers of inflammation and continuous metabolic traits
The associations between the 6 genetic variants of inflammation and 10 continuous metabolic traits are reported in Table 2. Only one SNP displayed a nominal evidence of association: rs1800871 (IL-10) with LDL (beta = -0.068 ± 1.006, P = 0.010).

**Association between genetic markers of inflammation and binary metabolic traits**

The associations between the 6 genetic markers of inflammation and 8 binary metabolic traits are reported in Table 3. One nominally significant association was found: rs7305618 (HNF1A) with family history of hypertension (1.389 [1.054-1.829] p=0.020). No P-value was significant after Bonferroni correction for multiple testing.

**Discussion**

In the present study, we assessed the association of 6 common genetic variants in 5 inflammation-related genes with 10 continuous and 8 binary metabolic traits in 1462 children from the Mexican population. We found one nominal associations between a genetic variant and the continuous traits. Subsequently, we only found two nominal associations between genetic variants and continuous / binary metabolic traits. No P-value resisted to a Bonferroni correction for multiple testing (P < 4.6 x 10^{-4}). The number of significant P-values obtained in this experiment at the 0.05 alpha level was less than the number of associations expected by chance (~ 5). Overall, our negative results do not suggest an association between inflammation-associated SNPs and metabolic traits in Mexican children. This is in line with previous reports from literature, that at best suggest a possible association between inflammation and cardiovascular events (Elliott et al. 2009; Fall et al. 2015; Hingorani 2012; Rafiq et al. 2008; Raman et al. 2013; Varbo et al. 2013; Welsh et al. 2010). Our findings are also supported by the discoveries of hypothesis-free genome-wide association studies for metabolic traits that show a
limited overlap with genetic markers of inflammation to date (Ehret et al. 2011; Locke et al. 2015a; Mahajan et al. 2014; Raman et al. 2013; Willer et al. 2013).

Power calculations on the standard trait BMI indicate that we only have a fair likelihood to identify associations at the nominal and Bonferroni corrected levels (Supplementary figure 1 and 2). Therefore, we cannot totally exclude that the nominal associations reported here are actually true subtle positive results. For instance, we found that the rs7305618 SNP near HNF1A was nominally associated with a family history of hypertension. The HNF1A gene encodes hepatic nuclear factor 1 alpha (HNF1a), a transcription factor expressed in the liver, pancreas, gut and kidney (Ban et al. 2002). Mutations in the HNF1A gene account for approximately 70% of cases of maturity onset diabetes of the young (MODY) (VaxiHaire et al. 1995). HNF1A mutation carriers display a distinct hypertension status (Owen et al. 2002). HNF-1a is an essential transcription factor in nephron development and rare coding loss-of-function mutations in HNF1A lead to renal malformations and renal dysfunction in mice and humans (Bingham et al. 2000; Malecki et al. 2005; Pontoglio et al. 1996). Testing the associations of the HNF1A rs7305618 SNP with adult hypertension in independent studies may therefore be relevant. Similarly, the association of rs1800871 (IL-10) with LDL is indirectly supported by previous reports in literature. While the adenovirus-mediated gene transfer of interleukin-10 in an hyperlipidemic LDLr knock-out mouse model results in lowering of cholesterol levels and attenuation of atherogenesis, interleukin-10 deficiency in a distinct hyperlipidemic apolipoprotein E knock-out mouse model leads to an increase of LDL and atherosclerosis (Caligiuri et al. 2003; Von Der Thusen et al. 2001). However, further studies in independent Mexican children populations are needed to confirm these nominal associations. No
study in children has assessed the association of genetic markers of inflammation with metabolic traits, making any comparisons to our data difficult.

Our study has several strengths. It is the first to explore the associations of a representative list of genetic variants related to inflammation with metabolic traits in children and in the Mexican population. Additionally, we assessed diverse metabolic traits including both continuous and binary variables. Limitations of the study include an under-optimal statistical power to identify even substantial genetic effects, especially after corrections for multiple tests (Supplementary Figure 1 and 2). Additionally, the list of SNPs related to inflammation that we assessed did not include the more recent GWAS discoveries for inflammation traits (Raman et al. 2013). We did not assess the association of these SNPs with intermediate inflammatory serum markers (e.g. CRP, sICAM-1, IL-6, soluble P-selectin). Finally, using ancestry informative markers to adjust for potential population stratification was not performed in this study.

In conclusion, the association study of 6 SNPs in 5 inflammation-related genes with 10 continuous and 8 binary cardio-metabolic traits in 1462 Mexican children does not suggest an association between inflammation-associated SNPs, obesity and its metabolic complications. Additional studies with larger sample sizes, a more exhaustive panel of SNPs and the availability of both inflammatory serum biomarkers and clinical traits in Mexican and other populations will provide a more definitive answer to this important research topic.

Acknowledgements

We acknowledge all the participants of the study. We acknowledge Hudson Reddon and Amel Lamri for their technical assistance.

Supplementary information
Supplementary information is available at the PeerJ website.
References

Avery CL, He Q, North KE, Ambite JL, Boerwinkle E, Fornage M, Hindorff LA, Kooperberg C, Meigs JB, and Pankow JS. 2011. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. *PLoS genetics* 7:e1002322.

Ban N, Yamada Y, Someya Y, Miyawaki K, Ihara Y, Hosokawa M, Toyokuni S, Tsuda K, and Seino Y. 2002. Hepatocyte nuclear factor-1α recruits the transcriptional co-activator p300 on the GLUT2 gene promoter. *Diabetes* 51:1409-1418.

Barquera S, Campos-Nonato I, Hernández-Barrera L, Flores M, Durazo-Arvizu R, Kanter R, and Rivera JA. 2009. Obesity and central adiposity in Mexican adults: results from the Mexican National Health and Nutrition Survey 2006. *salud publica de mexico* 51:S595-S603.

Bingham C, Ellard S, Allen L, Bulman M, Shepherd M, Frayling T, Berry PJ, Clark PM, Lindner T, Bell GI, Ryffel GU, Nicholls AJ, and Hattersley AT. 2000. Abnormal nephron development associated with a frameshift mutation in the transcription factor hepatocyte nuclear factor-1 beta. *Kidney Int* 57:898-907. 10.1046/j.1523-1755.2000.057003898.x

Brunner EJ, Kivimäki M, Witte DR, Lawlor DA, Smith GD, Cooper JA, Miller M, Lowe GD, Rumley A, and Casas JP. 2008. Inflammation, insulin resistance, and diabetes—Mendelian randomization using CRP haplotypes points upstream. *PLoS medicine* 5:e155.

Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, and Nicoletti A. 2003. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. *Mol Med* 9:10-17.

Castillo EH, Borges G, Talavera JO, Orozco R, Vargas-Alemán C, Huitrón-Bravo G, Diaz-Montiel JC, Castañón S, and Salmerón J. 2007. Body mass index and the prevalence of metabolic syndrome among children and adolescents in two Mexican populations. *Journal of adolescent health* 40:521-526.

Consortium I-RMRA. 2012. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *The Lancet* 379:1214-1224.

Consortium STD. 2014. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. *Nature* 506:97-101.

Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y, Heath S, Sober S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milaneschi Y, Parker AN, Fava C, Chambers JC, Fox ER, Kumari M, Go MJ, van der Harst P, Kao WH, Sjogren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu Y, Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Nguyen KD, Lehtimaki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uiterwaal CS, Adeyemo A, Palmas W, Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND, Aspelund T, Garcia M, Chang YP, O'Connell JR, Steinle NI, Grobbee DE, Arking DE, Kardia SL, Morrison AC, Hernandez D, Najjar S, McArule WL, Hadley D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby JP, Lawrence RW, Clarke R, Hopewell JC, Ongen H, Dreisbach AW, Li Y, Young JH, Bis JC, Kahonen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M, Pattaro C, Bolton JA, Kottgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J, Kulkarni SR, Bornstein SR, Grassler J, Groop L, Voight BF, Kettenun J, Howard P, Taylor A, Guerrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle LL, Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand SM, Staessen JA, Wang TJ, Burton PR, Soler Artigas M, Dong Y, Snieder H,
Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL, Wiggins KL, Doumatey A,

Shriner D, Veldre G, Vigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A,

Thelle DS, Corsi AM, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y,

Ogihara T, Okhubo T, Okamura T, Ueshima H, Umemura S, Eyheramendy S, Meitinger T,

Wichmann HE, Cho YS, Kim HL, Lee JY, Scott J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith

GD, Wong A, Narisu N, Stancakova A, Raffel LJ, Yao J, Kathiresan S, O'Donnell CJ, Schwartz SM,

Ikram MA, Longstreth WT, Jr., Mosley TH, Seshadri S, Shrine NR, Wain LV, Morken MA, Swift AJ,

Laitinen J, Prokopenko I, Zitting P, Hooper JA, Hercberg S, Lathrop M, Zelenika D, Demirkan A,

Mangino M, Spector TD, Zhai G, Meitinger T, Wu X, Laitinen J, Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danes J, Rasheed A, Goel A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS, Mani K, Yajnik CS, Hofman A,

Mattace-Raso FU, Oostra BA, Demirkiran A, Isaacs A, Rivadeneira F, Lakatta EG, Orru M, Scuteri A,

Ala-Korpela M, Kangas AJ, Lyytikainen LP, Soininen P, Tukiainen T, Wurtz P, Ong RT, Dorr M,

Kroemer HK, Volker U, Volzeck H, Galan P, Hercberg S, Lathrop M, Zelenika D, Deloukas P,

Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P, Terzic J, Kumar MV, Denniff M,

Zukowska-Szczechowska E, Van F, Wagenknecht CW, Guo X, Rotini C, Bots ML, Brand E, Samani NJ, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M,

Hveem K, Palmer L, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, Ganesh SK,

Wong TY, Tai ES, Cooper RS, Laakso M, Raeb PR, Morris RW, Dominiczak AF, Kivimaki M, Marmot MG, Meirhaeghe A, Kristiansson K, Nuotio ML, Kobl M, Grallert H, Dehghan A, Kuningas M, de Vries PS, de Bruijn RF, Willems SM, Heikkila K, Silventoinen K, Pietilainen KH, Legry V, Giedraitis V, Goumidi L, Syvanen AC, Strauch K, Koenig W, Lichtner P, Herder C, Palotie A, Menni C, Uitterlinden AG, Kovanen P, Kuulasmaa K, Havulinna AS, Moreno LA, Gonzalez-Gross M, Evans A, Tregouet DA, Yarnell JW, Virtamo J, Ribot J, Rettig R, Umda M, Strachan DP, Witteman JC, Hartikainen AL, Beckmann JS, Boerwinkle E, Vasan RS, Boehrke M, Larson MR, Jarvelin MR, Psaty BM, Abecasis GR, Chakravarti A, Elliott P, van Duijn CM, Newton-Cheh C, Levy D, Caufield MJ, and Johnson T. 2011. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478:103-109.

10.1038/nature10405

Elks CE, Den Hoed M, Zhao JH, Sharp SJ, Wareham NJ, Loos RJ, and Ong JK. 2012. Variability in the heritability of body mass index: a systematic review and meta-regression. Frontiers in endocrinology 3.

Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, and Bennett D. 2009. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302:37-48.

Fall T, Hagg S, Ploner A, Magi R, Fischer K, Draisma HH, Sarin AP, Benyamin B, Ladenvall C, Akerlund M, Kals M, Esko T, Nelson CP, Kruit M, Huikari V, Gang L, Meirahege A, Kristiansson K, Nuotio ML, Kobb M, Galer K, Debhaj H, Kuningas M, de Vries PS, de Bruijn RF, Willems SM, Heikkila K, Silventoinen K, Pietilainen KH, Legry V, Giedraits V, Gumil D, Syvanen AC, Strauch K, Koenig W, Lichtner P, Herder C, Palotie A, Menni C, Uitterlinden AG, Kuulasmaa K, Havulinna AS, Moreno LA, Gonzalez-Gross M, Evans A, Tregouet DA, Yarnell JW, Virtamo J, Veronesi G, Perala M, Arveiler D, Brimbalia P, Lind L, Kaprio J, Hofman A, Bricker BH, van Duijn CM, Ikram MA, Franco OH, Cottel D, Dallongeville J, Hall AS, Jula A, Cobin MD, Penninx BW, Peters A, Gieger C, Samani NJ, Montgomery GW, Whitfield JB, Martin NG, Groop L, Spector TD, Magnusson PK, Amouyel P, Boomsma DJ, Nilsson PM, Jarvelin MR, Lyssenko V, Metspalsu A, Strachan DP, Salomaa V, Ripatti S, Pedersen NL, Prokopenko I, McCarthy MI, and Ingelsson E. 2015. Age- and Sex-Specific Causal Effects of Adiposity on Cardiovascular Risk Factors. Diabetes. 10.2337/db14-0988

Hingorani AD, Casas, J.P. 2012. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet 379:1214-1224.
Hossain P, Kawar B, and El Nahas M. 2007. Obesity and diabetes in the developing world—a growing challenge. *New England Journal of Medicine* 356:213-215.

Hotamisligil GS. 2006. Inflammation and metabolic disorders. *Nature* 444:860-867.

Isordia-Salas I, Santiago-Germán D, Rodríguez-Navarro H, Almaráz-Delgado M, Leaños-Miranda A, Anaya-Gómez F, Borrayo-Sánchez G, and Majluf-Cruz A. 2011. Prevalence of metabolic syndrome components in an urban Mexican sample: comparison between two classifications. *Experimental Diabetes Research* 2012.

Kalra S, Gandhi A, Kalra B, and Agrawal N. 2009. Management of dyslipidemia in children. *Diabetol Metab Syndr* 1:26. 10.1186/1758-5996-1-26

Karelis A, Brochu M, and Rabasa-Lhoret R. 2004. Can we identify metabolically healthy but obese individuals (MHO)? *Diabetes & metabolism* 30:569-572.

Kilpelainen TO, Laaksonen DE, Lakka TA, Herder C, Koenig W, Lindstrom J, Eriksson JG, Uusitupa M, Kolb H, Laakso M, and Tuomilehto J. 2010. The rs1800629 polymorphism in the TNF gene interacts with physical activity on the changes in C-reactive protein levels in the Finnish Diabetes Prevention Study. *Exp Clin Endocrinol Diabetes* 118:757-759. 10.1055/s-0030-1249686

Kramar S, Gandhi A, Kalra B, and Agrawal N. 2009. Management of dyslipidemia in children. *Diabetol Metab Syndr* 1:26. 10.1186/1758-5996-1-26

Klein J, Zinnam B, and Retnakaran R. 2013. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. *Annals of internal medicine* 159:758-769.

León-Mimila P, Villamil-Ramírez H, Villalobos-Comparán M, Villarreal-Molina T, Romero-Hidalgo S, López-Contreras B, Gutiérrez-Vidal R, Vega-Badillo J, Jacobo-Albavera L, and Posadas-Romeros C. 2013. Contribution of common genetic variants to obesity and obesity-related traits in mexican children and adults. *Plos one* 8:e70640.

Lisker R, Ramirez E, and Babinsky V. 1996. Genetic structure of autochthonous populations of Mesoamerica: Mexico. *Human Biology* 68:395-404.

Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, and Yang J. 2015a. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 518:197-206.

Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, and Yang J. 2015b. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 518:197-206.

Lisker RR, Babinsky V., 1996. Genetic structure of autochthonous populations of Meso-America: Mexico. *Human Biology* 68:395-404.
FS, Cornelis MC, Couper DJ, Crenshaw AT, van Dam RM, Danesh J, Das D, de Faire U, Dedoussis G, Deloukas P, Dimas AS, Dina C, Doney AS, Donnelly PJ, Dorkhan M, van Duijn C, Dupuis J, Edkins S, Elliott P, Emilsson V, Erbel R, Eriksson JG, Escobedo J, Escoffery T, Eury E, Florez JC, Fontanillas P, Forouhi NG, Forsen T, Fox C, Fraser RM, Frayling TM, Froelich P, Frossard P, Gao Y, Gertow K, Gieger C, Gigante B, Grammer H, Grant GB, Groop LC, Groves CJ, Grundberg E, Guiducci C, Hamsten A, Han BG, Harke K, Hassanali N, Hattersley AT, Hayward C, Hedman AK, Herder C, Hofman A, Holmen OL, Hovingh K, Hreidarsson AB, Hu C, Hu FB, Hui J, Humphries SE, Hunt SE, Hunter DJ, Hveem K, Hydrie ZI, Ikegami H, Illig T, Ingelsson E, Islam M, Isomaa B, Jackson AU, Jafar T, James A, Jia W, Jockel KH, Jonsson A, Jowett JB, Kadowaki T, Kang HM, Kanoni S, Kao WH, Kathiresan S, Kato N, Katulanda P, Keinanen-Kiukaanniemi KM, Kelly AM, Khan H, Khaw KT, Khor CC, Kim HL, Kim S, Kim YJ, Kinnunen L, Klopp N, Kong A, Korpi-Hyovalti E, Kowlussur S, Kraft P, Kravic J, Kristensen MM, Krithika S, Kumar A, Kuusisto J, Kwak SH, Laakso M, Lager V, Lakka TA, Langenberg C, Langford C, Lawrence R, Leander K, Lee JM, Lee NR, Li M, Li X, Li Y, Liang J, Liju S, Lim WY, Lind L, Lindgren CM, Lindholm E, Liu CT, Liu JJ, Lobbens S, Long J, Loos RJ, Lu W, Luan J, Lyssenko V, Ma RC, Maeda S, Magi R, Mannisto S, Matthews DR, Meigs JB, Melander O, Metspalu A, Meyer J, Mirza G, Mikhailov E, Moebus S, Mohan V, Mohile KL, Morris AD, Mulhuisen TW, Muller-Nurasyid M, Musk B, Nakamura J, Nakashima E, Navarro P, Ng PK, Nica AC, Nilsson PM, Njolstad I, Nothen MM, Ohnaka K, Ong TH, Owen KR, Palmer CN, Pankow JS, Park KS, Parkin M, Pechlishan NL, Pedersen NL, Perry JR, Peters A, Pinidilyapathirage JM, Platou CG, Potter S, Price JF, Qi L, Radha V, Rallidis L, Rasheed A, Rathman W, Rauramaa R, Raychaudhuri S, Rayner NW, Rees SD, Rehnborg E, Ripatti S, Robertson N, Roden M, Rossin EJ, Rudan I, Rybin D, Saaristo TE, Salomaa V, Saltevo J, Samuel M, Sanghera DK, Saramies J, Scott J, Scott LJ, Scott RA, Segre AV, Sehmi J, Sennblad B, Shah N, Shah S, Shera AS, Shu XO, Shuldiner AR, Sigurdsson G, Sijbrands E, Silveira A, Sim X, Sivapalaratnam S, Small KS, So WY, Stancakova A, Stefansson K, Steinbach G, Steinthorsdottir V, Stirrups K, Strawbridge RJ, Stringham HM, Sun Q, Suo C, Syvanen AC, Takayanagi R, Takeuchi F, Tay WT, Teslovich TM, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tikkanen E, Trakalo J, Tremoli E, Trip MD, Tsai FJ, Tuomilehto J, Uitterlinden AG, Valladares-Salgado A, Vedantam S, Veglia F, Voight BF, Wang C, Wareham NJ, Wenneau R, Wickremasinghe AR, Wilsgaard T, Wilson JF, Wiltshire S, Winckler W, Wong TY, Wood AR, Wu JY, Wu Y, Yamamoto K, Yamauchi T, Yang M, Yengo L, Yokota M, Young R, Zabaneh D, Zhang F, Zhang R, Zheng W, Zimmet PZ, Altshuler D, Bowden DW, Cho YS, Cox NJ, Cruz M, Hanis CL, Koener J, Lee YJ, Seielstad M, Teo YY, Boehnke M, Parra EJ, Chambers JC, Tai ES, McCarthy MI, and Morris AP. 2014. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 46:234-244. 10.1038/ng.2897

Norden-Krichmar TM, Gizer IR, Libiger O, Wilhelmsen KC, Ehlers CL, and Schork NJ. 2014. Correlation analysis of genetic admixture and social identification with body mass index in a Native American community. American Journal of Human Biology 26:347-360.

Ogden CL, Carroll MD, Curtin LR, Lamb MM, and Flegal KM. 2010. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 303:242-249.

Ogden CL, Carroll MD, Kit BK, and Flegal KM. 2014. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311:806-814.

Ortega L, Navarro P, Riestra P, Gavela-Perez T, Soriano-Guillen L, and Garces C. 2014. Association of resistin polymorphisms with resistin levels and lipid profile in children. Mol Biol Rep 41:7659-7664. 10.1007/s11033-014-3658-8
Owen KR, Shepherd M, Stride A, Ellard S, and Hattersley AT. 2002. Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics. *Diabet Med* 19:758-761.

Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, and Yaniv M. 1996. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. *Cell* 84:575-585.

Rafiq S, Melzer D, Weedon M, Lango H, Saxena R, Scott L, Palmer C, Morris A, McCarthy M, and Ferrucci L. 2008. Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. *Diabetologia* 51:2205-2213.

Raman K, Chong M, Akhtar-Danesh G-G, D'Mello M, Hasso R, Ross S, Xu F, and Paré G. 2013. Genetic markers of inflammation and their role in cardiovascular disease. *Canadian Journal of Cardiology* 29:67-74.

Rivera JA, Barquera S, Campirano F, Campos I, Safdie M, and Tovar V. 2002. Epidemiological and nutritional transition in Mexico: rapid increase of non-communicable chronic diseases and obesity. *Public health nutrition* 5:113-122.

Tounian P, Aggoun Y, Dubern B, Varille V, Guy-Grand B, Sidi D, Girardet J-P, and Bonnet D. 2001. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. *The Lancet* 358:1400-1404.

Varbo A, Benn M, Tybjærg-Hansen A, and Nordestgaard BG. 2013. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. *Circulation* 128:1298-1309.

Vattikuti S, Guo J, and Chow CC. 2012. Heritability and genetic correlations explained by common SNPs for metabolic syndrome traits. *PLoS genetics* 8:e1002637.

VaxiHaire M, Valérie Boccio AP, Vigouroux C, Terwilliger J, Passa P, Beckmann JS, and Velho G. 1995. A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q. *Nature Genet* 9:418-423.

Von Der Thusen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, and Biessen EA. 2001. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. *FASEB J* 15:2730-2732. 10.1096/fj.01-0483fje

Welsh P, Polisecki E, Robertson M, Jahn S, Buckley BM, de Craen AJ, Ford I, Jukema JW, Macfarlane PW, and Packard CJ. 2010. Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach. *The Journal of Clinical Endocrinology & Metabolism* 95:93-99.
Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den Hertog HM, Do R, Donnelly LA, Ehret GB, Esko T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF, Gurdasani D, Heikkilä K, Hypponen E, Isaacs A, Jackson AU, Johansson A, Johnson T, Kaakinen M, Kettunen J, Kleber ME, Li X, Luo J, Lyytikainen LP, Magnusson PK, Mangino M, Mihailov E, Montasser ME, Muller-Navaret M, Nolte IM, O'Connell J, Palmer CD, Perola M, Petersen AK, Sanna S, Saxena R, Service SK, Shah S, Shungin D, Sidore C, Song C, Strawbridge RJ, Surakka I, Tanaka T, Teslovich TM, Thorleifsson G, Van den Herik EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D, Asiki G, Barroso I, Been LF, Bolton NL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M, Doney AS, Doug H, Elliott P, Eyjolfsson GI, Gigante B, Goodarzi MO, Grallert H, Gravito ML, Groves CJ, Hallmansk A, Hartikainen AL, Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, Jones MR, Kastelein JJ, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, Lethtimaki T, Lin SY, Lindstrom J, Loos R, Mach F, McArdle WL, Meisinger C, Mitchell BD, Muller G, Nagaraja R, Namasivayam N, Nenimieni TV, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla C, Poult A, Rader DJ, Reilly MP, Ridker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, Seeley J, Silander K, Stancakova A, Stirrups K, Swift AJ, Tiet J, Uitterlinden AG, van den Lijt J, Vedantam S, Wainwright N, Wijmenga C, Wild SH, Willemse G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair LS, Arveider D, Assimes I, Bandinelli S, Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YD, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Keran AB, Ferrienes J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudnason V, Gyllensten U, Hamsten A, Harris B, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, Humphries SE, Hunt SC, Hveem K, Iribarren C, Jarvelin MR, Jula A, Kahonen M, Kaprio J, Kesaniemi A, Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, Laakso M, Lakk TA, Lind L, Lindgren CM, Martin NG, Marz W, McCarthy MJ, McKenzie CA, Meneton P, Metsalu A, Moinlou L, Morris AD, Munroe PB, Njolsdal I, Pedersen N, Power C, Ramstaller PP, Price JF, Psaty BM, Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sandhra DK, Saramies J, Schwarz PE, Sheu WH, Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tao YB, Tremoli E, Tuomilehto J, Uusitupa M, van Duijn CM, Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB, Wolfenbuttel BH, Ordovas JM, Boerwinkle E, Palmer CN, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Kathiresan S, Mohlke KL, Ingelsson E, and Abecasis GR. 2013. Discovery and refinement of loci associated with lipid levels. Nat Genet 45:1274-1283. 10.1038/ng.2797

Yazdi FT, Clee SM, and Meyre D. 2015. Obesity genetics in mouse and human: back and forth, and back again. PeerJ 3:e856. 10.7717/peerj.856
### Table 1. Characteristics of the Mexican children population.

| Trait                                      | Mean ± Standard Deviation | Sample Size |
|--------------------------------------------|---------------------------|-------------|
| Sex (% Male/Female)                        | 53.0/47.0                 | 775/687     |
| Age (Years)                                | 9.24 ± 2.07               | 1462        |
| BMI (Kg/m²)                                | 19.65 ± 4.20              | 1461        |
| Waist to hip ratio                         | 0.85 ± 0.06               | 1417        |
| Systolic blood pressure (mmHg)             | 98.58 ± 10.88             | 1457        |
| Diastolic blood pressure (mmHg)            | 66.25 ± 8.80              | 1458        |
| Low density lipoprotein-cholesterol (mg/dl)| 102.43 ± 26.43            | 1462        |
| High density lipoprotein-cholesterol (mg/dl)| 50.58 ± 12.82            | 1462        |
| Total cholesterol (mg/dl)                  | 157.27 ± 33.53            | 1462        |
| Triglycerides (mg/dl)                      | 93.67 ± 49.69             | 1462        |
| Fasting glucose (mmol/l)                   | 4.57 ± 0.53               | 1461        |
| Fasting insulin (mIU/l)                    | 9.10 ± 7.05               | 1148        |
| Underweight (%)                            | 1.40                      | 1462        |
| Normal weight (%)                          | 49.40                     | 1462        |
| Overweight (%)                             | 21.30                     | 1462        |
| Obese (%)                                  | 27.90                     | 1462        |
| Hypertension (%)                           | 1.50                      | 1452        |
| Hyperglycemia (%)                          | 3.10                      | 1456        |
| Dyslipidemia (%)                           | 34.90                     | 1457        |
| Type 2 diabetes family history (%)         | 11.98                     | 1461        |
| Hypertension family history (%)            | 16.29                     | 1461        |
| Overweight / obesity family history (%)    | 53.05                     | 1461        |
Table 2. Association between 6 genetic markers of inflammation and 10 continuous metabolic traits.

|            | BMI     | WHR     | SBP     | DBP     | LDL     | HDL     | TC      | TG      | FG      | FI      |
|------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| rs1137101  | 0.002 ±  | -0.003 ± | -0.001 ± | 0.003 ± | -0.023 ± | -0.009 ± | -0.008 ± | -0.007 ± | -0.019 ± | -0.008 ± |
| (LEPR)     | (0.83)  | (0.19) | (0.83) | (0.50) | (0.38) | (0.73) | (0.27) | (0.66) | (0.47) | (0.78) |
| rs7305618  | -0.003 ± | -0.004 ± | -0.010 ± | 0.002 ± | 0.011 ± | 0.006 ± | -0.006 ± | -0.016 ± | 0.010 ±  | 0.029 ±  |
| (HNF1A)    | (0.76)  | (0.319) | (0.15) | (0.83) | (0.69) | (0.717) | (0.57) | (0.53) | (0.71) | (0.46) |
| rs1800629  | 0.002 ±  | 0.008 ±  | 0.022 ±  | 0.005 ±  | 0.002 ±  | 0.037 ±  | 0.006 ±  | 0.021 ±  | 0.031 ±  | 0.000 ±  |
| (TNFA)     | (0.93)  | (0.75) | (0.37) | (0.85) | (0.93) | (1.156) | (0.81) | (0.42) | (0.24) | (0.99) |
| rs1800896  | -0.001 ± | -0.003 ± | -0.005 ± | 0.004 ±  | -0.006 ± | 0.012 ±  | -0.001 ± | -0.018 ± | 0.034 ±  | 3.89x10^-5 ± |
| (IL-10)    | (0.94)  | (0.38) | (0.28) | (0.53) | (0.84) | (0.566) | (0.92) | (0.37) | (0.21) | (0.99) |
| rs1800871  | -0.005 ± | -0.001 ± | -0.004 ± | -0.005 ± | -0.005 ± | -0.011 ± | 0.010 ±  | -0.006 ± | -0.024 ± | -0.007 ± |
| (IL-10)    | (0.49)  | (0.57) | (0.33) | (0.31) | (0.31) | (0.489) | (0.19) | (0.56) | (0.82) | (0.37) |
| rs1862513  | -0.020 ± | -0.005 ± | 0.002 ±  | 0.007 ±  | 0.022 ±  | 0.052 ±  | 0.007 ±  | 0.017 ±  | 0.010 ±  | -0.070 ± |
| (RETN)     | (0.08)  | (0.17) | (0.39) | (0.82) | (0.41) | (0.765) | (0.24) | (0.54) | (0.71) | (0.09) |

Values in bold indicate P value < 0.05; data are presented as beta ± standard error (P-value). a Natural logarithmic transformation applied. b SNP analyzed under the dominant model.
Table 3. Association between 6 genetic markers of inflammation and 8 binary metabolic traits.

| SNP         | Normal weight vs. obese | Normal weight vs. overweight and obese | Hypertension | Hyperglycemia | Dyslipidemia | Type 2 diabetes family history | Hypertension family history | Overweight / obesity family history |
|-------------|-------------------------|----------------------------------------|--------------|---------------|--------------|-------------------------------|-----------------------------|-------------------------------|
| rs1137101 (LEPR) | 0.052 [0.886-1.253] (0.56) | 1.004 [0.867-1.162] (0.96) | 1.415 [0.782-2.562] (0.25) | 0.774 [0.505-1.186] (0.24) | 0.995 [0.853-1.161] (0.95) | 0.883 [0.706-1.105] (0.28) | 0.861 [0.707-1.049] (0.14) | 0.925 [0.799-1.072] (0.30) |
| rs7305618 (HNF1A) | 0.849 [0.652-1.106] (0.23) | 0.879 [0.704-1.097] (0.25) | 0.732 [0.263-2.038] (0.55) | 0.938 [0.485-1.816] (0.85) | 0.871 [0.688-1.102] (0.25) | 1.347 [0.988-1.837] (0.06) | 1.389 [1.054-1.829] (0.02) | 1.050 [0.841-1.311] (0.67) |
| rs1800629 (TNFA) | 1.175 [0.767-1.609] (0.46) | 1.110 [0.767-1.609] (0.58) | 0.793 [0.244-2.576] (0.70) | 1.084 [0.738-1.592] (0.68) | 0.652 [0.336-1.266] (0.21) | 0.553 [0.300-1.018] (0.06) | 1.020 [0.702-1.482] (0.92) | 1.104 [0.927-1.314] (0.27) |
| rs1800896 (IL-10) | 1.011 [0.825-1.239] (0.92) | 1.050 [0.883-1.249] (0.58) | 0.827 [0.393-1.743] (0.62) | 1.348 [0.834-2.180] (0.22) | 1.041 [0.868-1.238] (0.67) | 1.060 [0.813-1.383] (0.67) | 0.991 [0.785-1.253] (0.94) | 1.104 [0.927-1.314] (0.27) |
| rs1800871 (IL-10) | 0.929 [0.778-1.108] (0.41) | 0.962 [0.827-1.118] (0.61) | 0.851 [0.457-1.584] (0.61) | 1.152 [0.750-1.769] (0.52) | 0.944 [0.805-1.107] (0.48) | 1.015 [0.807-1.277] (0.90) | 0.876 [0.714-1.075] (0.20) | 0.906 [0.779-1.054] (0.20) |
| rs1862513 (RETN) | 0.785 [0.585-1.052] (0.11) | 0.932 [0.736-1.180] (0.56) | 1.065 [0.416-2.726] (0.90) | 0.677 [0.310-1.477] (0.33) | 0.941 [0.733-1.209] (0.64) | 1.135 [0.801-1.669] (0.48) | 0.981 [0.713-1.350] (0.91) | 0.984 [0.777-1.246] (0.89) |

Values in bold indicate P value < 0.05; data are presented as beta [confidence interval] (P-value). a SNP analyzed under the dominant mode.